Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- ARCALYST net revenue grew 85% year-over-year to $78.9 million in Q1 2024. - Total prescribers of ARCALYST grew to approximately 2,000 at the end of Q1. - Plans to initiate a Phase 2b trial with Abiprubart in Sjögren's Disease to provide a meaningful benefit to patients. - Revenue guidance for 2024 increased from $360 million to $380 million to $370 million to $390 million. - The company expects to remain cash flow positive on an annual basis. Price Impact Rating: bullish Impact Horizon Rating: short-term Type: Earnings
- ARCALYST net revenue grew 85% year-over-year to $78.9 million in Q1 2024.
- Total prescribers of ARCALYST grew to approximately 2,000 at the end of Q1.
- Plans to initiate a Phase 2b trial with Abiprubart in Sjögren's Disease to provide a meaningful benefit to patients.
- Revenue guidance for 2024 increased from $360 million to $380 million to $370 million to $390 million.
- The company expects to remain cash flow positive on an annual basis.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.